- The Japanese Ministry of Health, Labour and Welfare approves Allergan plc's (NYSE:AGN) BOTOX Vista (botulinum toxin type A product) for the temporary improvement in the appearance of lateral canthal lines (crow's feet lines) in adult patients under the age of 65
- BOTOX, first approved for therapeutic use in the U.S. in 1989, is approved for sale in 94 countries around the world.